Clinical trials: Extensive Disease Small Cell Lung Cancer
Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
- Trial name
- NCT03898791
- Testing
- LY3295668 Erbumine
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
The purpose of this study is to evaluate whether increasing or maintaining hemoglobin concentrations with darbepoetin alfa, when administered with platinum-containing chemotherapy in subjects with previously untreated…
- Trial name
- NCT00119613
- Testing
- darbepoetin alfa
- Volunteers
- 600 people
- Sponsor
- Amgen
Small Cell Lung Cancer
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Comparison of two combination chemotherapies in the treatment of patients with SLCL
- Trial name
- NCT00168896
- Testing
- Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
- Where
- Germany
- Volunteers
- 286 people
- Sponsor
- Charite University, Berlin, Germany
Anlotinib, Durvalumab
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
- Conditions
- Anlotinib, Durvalumab, Small Cell Lung Cancer
- Trial name
- NCT04314297
- Testing
- Anlotinib In Combination With Durvalumab
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Extensive-Stage Small Cell Lung Cancer
A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer
This is a phase I, open-label, multi-center, non-randomized, 2-part first time inhuman (FTIH) study for SYHA1807. Part 1 is a dose escalation phase to determine the recommended phase 2 dose (RP2D) for SYHA1807 based on the…
- Trial name
- NCT04404543
- Testing
- SYHA1807
- Volunteers
- 71 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Small Cell Lung Cancer
A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
The purpose of this research study is to see if adding enoxaparin sodium to standard treatment with the chemotherapy drugs cisplatin and etoposide will help treat extensive stage SCLC.
- Trial name
- NCT00916669
- Testing
- Etoposide, Cisplatin, enoxaparin sodium
- Where
- 4 sites in United States
- Sponsor
- Massachusetts General Hospital
Lung Cancer
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00387660
- Testing
- carboplatin, irinotecan
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of California, Davis
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
- Trial name
- DART-NK-SCLC (NCT07480213)
- Testing
- EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of R-(-)-gossypol acetic acid when given together with cisplatin and etoposide in treating patients with advanced solid tumors or extensive stage small cell lung…
- Trial name
- NCT00544596
- Testing
- R-(-)-gossypol acetic acid, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Extensive-stage Small-cell Lung Cancer
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
- Trial name
- SCLC (NCT04894591)
- Testing
- Zepzelca
- Where
- 41 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Jazz Pharmaceuticals
Small Cell Lung Cancer
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
The purpose of the study is to document the activity and safety of single agent amrubicin, amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line treatment in extensive disease small cell lung…
- Trial name
- NCT00388960
- Testing
- Amrubicin, Cisplatin, Etoposide
- Where
- 25 sites in Belgium, Italy and 3 more
- Volunteers
- 99 people
- Sponsor
- Celgene
Small Cell Lung Carcinoma
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and…
- Trial name
- NCT01450761
- Testing
- Ipilimumab, Etoposide, Cisplatin
- Where
- 225 sites in United States, Argentina and 32 more
- Volunteers
- 1,351 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker…
- Trial name
- NCT05257551
- Testing
- Observation
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Tempus AI
Extensive-stage Small-cell Lung Cancer
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with…
- Trial name
- NCT07502300
- Testing
- BL-B01D1, Tislelizumab, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 562 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer
To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab
- Trial name
- NCT05882630
- Testing
- Surufatinib,Serplulimab,Etoposide,Carboplatin
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Small Cell Lung Cancer, Extensive Stage Lung Cancer
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small cell lung cancer, or SCLC, constitutes approximately 15% of the 170,000 new cases of lung cancer diagnosed annually in the United States.
- Conditions
- Small Cell Lung Cancer, Extensive Stage Lung Cancer, Chemonaive
- Trial name
- NCT00856830
- Testing
- Novel Drug Combination
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Extensive-stage Small Cell Lung Cancer
Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
Anlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer. A phase II clinical studies of small cell lung cancer (ALTER-1210) also showed that, compared with placebo, Anlotinib could improve…
- Trial name
- NCT03781869
- Testing
- Anlotinib Hydrochloride; etoposide and cisplatin, etoposide and cisplatin
- Volunteers
- 116 people
- Sponsor
- Third Military Medical University
Extensive Disease, First-Line
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.
- Conditions
- Extensive Disease, First-Line, Small Cell Lung Cancer
- Trial name
- NCT00812266
- Testing
- topotecan + cisplatin, Etoposide + carboplatin
- Where
- Denmark
- Volunteers
- 281 people
- Sponsor
- Danish Oncological Lung Cancer Group
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior…
- Trial name
- NCT02937818
- Testing
- Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
- Where
- 12 sites in Germany, Hungary and 3 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
This randomized phase I trial studies the side effects, best way to give, and best dose of docetaxel when given together with vaccine therapy and sargramostim in treating patients with metastatic lung cancer or metastatic…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00088933
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)